腹腔内5-FU联合rhTNFα和rhIFNγ预防大肠癌细胞株肝转移的实验研究  

A Study in the Prevention of Liver Metastases induced by Human Colonic Cancer Cells in the Nude Mice with Intraperitoneal 5-FU Plus rhTNFα and rhIFNγ

作　　者：冯国光[1] 周锡庚[1] 郁宝铭[1] 

机构地区：[1]上海第二医科大学附属瑞金医院外科,200025

出　　处：《外科理论与实践》1998年第3期146-147,共2页Journal of Surgery Concepts & Practice

基　　金：国家自然科学基金

摘　　要：探讨大肠癌细胞株肝转移的预防。方法:用裸鼠人结肠癌细胞肝转移模型观察术后早期腹腔内大剂量大容积5-FU联合重组人肿瘤坏死因子(rhTNFα)和重组人干扰素(rhIFNγ)预防肝转移的疗效。结果:5-FU40mg/生理盐水40ml·kg联合rhTNFα3万单位和rhIFNγ12万单位/kg腹腔内注射,每天一次,连续三天,可使裸鼠肝转移发生率减少83.33％,平均每只裸鼠肝转移瘤数减少95.24％,生存时间延长60.41％,疗效远优于单用5-FU组。结论:腹腔内化疗联合生物疗法为预防大肠癌根治术后肝转移提供了一种有效的辅助疗法。To probe the efficacy of combined regimen administered intraperitoneally preventing li-ver metastases of large bowel cancer. Methods: A model of liver metastases induced by human colonic cancer cells in the nude mice was used. The effect in preventing liver metastases by a combined regi-men: 5-FU 40mg/NS 40ml·kg + rhTNFα 30,000U and rhIFNγ120,000/kg Q.D.×3 administered intraperi-toneally was observed. Results: The incidence of liver metastases decreased by 83.33%, the mean nu-mber of metastatic liver nodules of each nude mice decreased by 95.24% and the mean survival time of prolonged by 60.41% in the treatment group as compared with the control group. Conclusions: The regi-men tested might be proved to be an effective adjuvant therapeutic modality in the prevention of liver metastases after curative resection of large bowel cancer.

关 键 词：腹腔内化疗 生物疗法 肝转移瘤 预防 大肠肿瘤 

分 类 号：R735.701[医药卫生—肿瘤] R735.340.6[医药卫生—临床医学]